Abstract
The level of expression of long non-coding RNA (LncRNA) X-inactive specific transcript (XIST) is up-regulated in pancreatic cancer (PC). However, the role of XIST in PC and the underlying mechanism are still unknown. The present study aimed to elucidate how XIST participates in PC and its potential target, miR-141-3p. We detected the XIST expression in PC tissues and cells by qRT-PCR. Cell proliferation was measured using a CCK8 kit, and the migration and invasion of cells was measured by Transwell assay. Silencing XIST and miR-141-3p was performed with transfection by Lipofectamine kit. Binding assay was conducted by luciferase reporter assay. Protein expression was examined by Western blot. These results indicate that (i) XIST is highly expressed in tumor tissues while miR-141-3p is down-regulated. (ii) Silencing XIST inhibits the pancreatic cell proliferation, migration and invasion. (iii) MiR-141-3p inhibitor alleviates the inhibitory effect by siXIST in PC cell lines. (iv) MiR-141-3p directly interacts with XIST and also negatively regulates transforming growth factor-β 2 (TGF-β2) expression. (v) Overexpression of XIST attenuates the inhibition of TGF-β2 expression by miR-141-3p. The conclusion, is that XIST could promote proliferation, migration and invasion of PC cells via miR-141-5p/TGF-β2 axis.
Highlights
Pancreatic cancer (PC) is a highly malignant gastrointestinal tumor, which is still considered largely incurable
We found siXIST could significantly decrease the expression of X-inactive specific transcript (XIST) (Figure 2A), and siXIST inhibited cell proliferation (Figure 2B)
The primary objective was to investigate the relationship between lncRNA XIST and miR-141-3p in human PC and to explore the underlying mechanisms that influence the cellular process in PC cells
Summary
Pancreatic cancer (PC) is a highly malignant gastrointestinal tumor, which is still considered largely incurable. The PC progression is too rapid to be under effective control. The 1-year relative survival rate of PC is approximately 20%, and more cruelly, the 5-year rate is 7% according to the American Cancer Society. Most patients survive less than 1 year after the first diagnosis [1,2]. Even though the traditional management, including surgical resection, radiotherapy and chemotherapy, has continuously improved, there is still a rising trend in the incidence and mortality of PC. PC is still a confusing issue to address it urgently. To explore the malignant progression of PC, especially the underlying mechanism, will provide a novel biomarker for the diagnosis and treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
